GPX4 and early-onset autosomal dominant Alzheimer disease: More recently, Yong et al. characterized Thonningianin A, a new compound that inhibits ferroptosis and described its use in Alzheimer’s disease therapy via GPX4 stimulation through the AMPK/Nrf2 pathway [12].